Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced
solid malignancies. The study is designed to determine the maximum tolerated dose and
dose-limiting toxicity of SN2310 Injectable Emulsion, and to characterize the
pharmacokinetics of SN2310 and SN-38 following intravenous administration of SN2310
Injectable Emulsion. Additionally, evaluation of side effects as a function of dose, and
observation of any anti-tumor effects of SN2310 Injectable Emulsion will be made.